ClinicalTrials.gg
CompletedNCT03267329Updated Apr 6, 2021

Duowell® vs. Telmisartan Monotherapy in Mild Dyslipidemia Patients With Hypertension

A Phase 4 interventional study of Duowell® and Telmisartan in Hypertension and Dyslipidemia, sponsored by Yuhan Corporation. Completed at 1 site in Korea, Republic of. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-04-06.

Sponsored by Yuhan Corporation · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 24 studies in Hypertension by Yuhan Corporation — 3 open to participants now, 3 under way, none of them phase 3. Hypertension · Yuhan Corporation.

Enrollment
12th of 23
80 · median 80
Started
2017
with 3 others
Phase 4
3 of 24
none open now
Registered
12th of 24
by date

Among the 24 studies in Hypertension by Yuhan Corporation, this one is the 12th largest by enrollment of the 23 interventional ones that give a count, is one of 4 that started in 2017, is one of 3 in phase 4, and was the 12th registered.

Hypertension

6,120 studies on the registry are indexed under Hypertension; 913 are open to participants now.

Browse Hypertension studies →

Open to participants now

3 of the 24 studies in Hypertension by Yuhan Corporation are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Hypertension by Yuhan Corporation, or all of them as a file.
02

Study summary

This study is to evaluate effect and safety on central blood pressure with Duowell compared to telmisartan monotherapy in mild dyslipidemia patients with hypertension during 16 weeks.

03

Conditions studied

  • Hypertension
  • Dyslipidemia
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 40 to 75 years old diagnosed with hypertension
  • at screening, SBP ≥ 140 mmHg
  • at randomization, 130 mmHg ≤ SBP ≤160 mmHg or 80 mmHg ≤ DBP ≤ 100 mmHg
  • at screening, ASCVD risk ≥ 5 %
  • Those who did not take the dyslipidemic medications during screening or who stopped medication for more than 2 months
  • at screening, 130 mg/dL ≤ Calculated (or Measured) Serum LDL-C ≤ 190 mg/dL
  • Pregnancy test negative and and who has agreed to perform effective during the clinical trial

Exclusion criteria

Exclusion Criteria (Any of the followings)

  • known to AT-1 receptor blockers or statins
  • Those who are treated with secondary hypertension during screening
  • Those who are being treated for malignant hypertension during screening
  • Those who are taking concurrent medication that may affect blood pressure during screening
  • Those who have been diagnosed with myocardial infarction or unstable angina or stroke within the last 6 months at screening
  • Patients with heart failure III-IV or \<40% within the last 6 months at screening
  • Patients with valve disease with hemodynamically significant (over moderate degree) obstructive
  • Those with known atrial fibrillation or atrioventricular conduction disturbance
  • Those who show the following numerical values during the screening test

    1. CPK ≥ 3 times the normal upper limit
    2. Serum Creatinine > 3 mg/dL
    3. Serum Potassium > 5.5 mmol/L
    4. or AST ≥ 3 times the upper normal limit
  • Those with known bilateral renal artery stenosis
  • Patients who underwent open heart surgery within 4 weeks prior to randomization and who had a cardiac surgery plan
  • Those taking statins within 8 weeks before randomization
  • Those with severe obstructive, limited or other pulmonary disease history
  • Those with non-cardiac disease that can significantly shorten the expected life span to less than 2 years (eg, severe cancer)
  • at screening, Anti- Ab, , Ab positive
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Duowell® Tab.

    Once daily during 16 wks

    Drug: Duowell®

  • Active comparator
    Telmisartan

    Once daily during 16 wks

    Drug: Telmisartan

Interventions

  • DrugDuowell®

    telmisartan 80mg/rosuvastatin 10mg for ASCVD risk=5%\~7.5% or telmisartan 80mg/rosuvastatin 20mg for ASCVD risk≥7.5%

  • telmisartan 80mg

06

What researchers measure

Primary outcomes

  1. Changes from baseline in mean central systolic blood pressure

    Time frame: at week 16

Secondary outcomes

  1. Changes from baseline in mean brachial systolic blood pressure

    Time frame: at week 4 and at week 16 and at week 28

  2. Changes from baseline in mean brachial pulse pressure

    Time frame: at week 4 and at week 16 and and at week 28

  3. Changes from mean brachial diastolic blood pressure

    Time frame: at week 4 and at week 16 and at week 28

  4. Changes from baseline in augmentation index

    Time frame: at week 16 and at week 28

  5. Changes from baseline in carotid femoral pulse wave velocity

    Time frame: at week 16 and at week 28

Other outcomes

  1. Changes from baseline in central blood pressure according to the frequency of access in mobile application

    Time frame: up to 4 weeks and up to 16 weeks

  2. Drug compliance between over 50% and less 50% of assessment in mobile application

    Time frame: at week 4 weeks and at week 16

  3. Drug compliance between over 50% and less 50% of assessment in mobile application

    Time frame: up to 3 months end of study

  4. Changes from the end of treatment in central systolic blood pressure after 3 months

    Time frame: at 3 months from the end of study

  5. Numbers of inconvenience reported by mobile application at each visit

    Time frame: up to 16 weeks

07

Study locations

1 site
  • Seoul National University Hospital
    Seoul, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Sep 2020, 35 months.

Of 35 industry-sponsored phase 4 interventional studies under Hypertension, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 35 months is above that.

Counting every sponsor, half of 161 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2017
First posted
Aug 30, 2017
StartActual
Sep 11, 2017
Primary completionActual
Sep 2, 2020
CompletionActual
Sep 2, 2020
Last update
Apr 6, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03267329
Lead sponsor
Yuhan Corporation
Responsible party
Sponsor
First posted
Aug 30, 2017
Start date
Sep 11, 2017
Primary completion
Sep 2, 2020
Completion
Sep 2, 2020
Last update
Apr 6, 2021

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion